Chinese Academy of Medical Sciences

🇨🇳China

Country: 🇨🇳China

Ownership: Private, Subsidiary

Established: 2004-07-08

Employees: -

Market Cap: -

Website: http://www.pinganzhengxing.com

Clinical Trials

Efficacy and Safety of Paclitaxel (Albumin-bound) Combination With Carboplatin in Ovarian Cancer.

Phase 2

Conditions: Ovarian Cancer

Interventions: Drug: Paclitaxel (albumin-bound)

First Posted Date: 2020-12-10

Last Posted Date: 2020-12-10

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 75

Registration Number: NCT04661696

Locations: 🇨🇳
National Cancer Center/ National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China

The Efficacy, Safety and Immunogenicity Study of Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19

Phase 3

Conditions: COVID-19

Interventions: Biological: Placebo
Biological: Inactivated SARS-CoV-2 Vaccine (Vero cell)

First Posted Date: 2020-12-09

Last Posted Date: 2021-02-10

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 34020

Registration Number: NCT04659239

Locations: 🇧🇷
CEMEC Pesquisa Clinica, São Bernardo do Campo, São Paulo, Brazil
🇲🇾
Hospital Sungai Buloh, Sungai Buloh, Selangor, Malaysia

Radiotherapy for Extracranial Oligometastatic Breast Cancer

Phase 3

Recruiting

Conditions: Breast Cancer Metastatic

Interventions: Drug: standard of care
Radiation: radiotherapy + standard of care

First Posted Date: 2020-11-30

Last Posted Date: 2022-01-11

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 170

Registration Number: NCT04646564

Locations: 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳
Wei-Fang Yang, Tai Zhou, Zhejiang, China

Safety and Preliminary Immunogenicity Study of Inactivated Vaccine for Prevention of Rotavirus Infection

Phase 1

Conditions: Rotavirus Infection

Interventions: Biological: Medium dosage IRV on a 0- and 28-day schedule
Biological: Low dosage IRV on a 0- and 28-day schedule
Biological: High dosage IRV on a 0- and 28-day schedule
Biological: Low dosage IRV on a 0- , 28- and 56-day schedule
Biological: High dosage IRV on a 0- , 28- and 56-day schedule
Biological: Placebo on day 0, 28
Biological: Placebo on day 0, 28, 56
Biological: Medium dosage IRV on a 0- , 28- and 56-day schedule

First Posted Date: 2020-11-13

Last Posted Date: 2020-12-10

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 32

Registration Number: NCT04626856

Locations: 🇨🇳
Henan Provincial Center for Disease Control and Prevention, Zhenzhou, Henan, China

Online Noninvasive Assessment of Human Brain Death and Deep Coma by Near-infrared Spectroscopy

Conditions: Brain Death
Coma

Interventions: Procedure: Oxygen supply of low-high-low procedure
Procedure: Oxygen supply of high-low-high procedure

First Posted Date: 2020-11-10

Last Posted Date: 2020-11-10

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 75

Registration Number: NCT04623294

Locations: 🇨🇳
NIRS assessment for brain death, Tianjin, Tianjin, China

Tislelizumab in Combination With Anlotinib With ES-SCLC as Maintenance Therapy After First Line Chemotherapy

Phase 2

Conditions: Small Cell Lung Carcinoma

Interventions: Drug: Tislelizumab
Drug: Anlotinib hydrochloride

First Posted Date: 2020-11-09

Last Posted Date: 2020-11-09

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 25

Registration Number: NCT04620837

Locations: 🇨🇳
National Cancer Center/Cancer Hospitial,Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China

PCI for Patients With ES-SCLC After RCT:a Prospective Randomized Study

Phase 3

Conditions: Small-cell Lung Cancer

Interventions: Radiation: prophylactic cranial irradiation

First Posted Date: 2020-09-02

Last Posted Date: 2020-09-02

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 414

Registration Number: NCT04535739

Locations: 🇨🇳
Department of Radiation Oncology, Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China

A Prospective Study of Hypothyroidism After Radiotherapy for Breast Cancer

Completed

Conditions: Radiation Toxicity
Breast Neoplasms
Hypothyroidism

First Posted Date: 2020-08-27

Last Posted Date: 2020-08-27

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 729

Registration Number: NCT04528225

Locations: 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China

Radiotherapy Combined With GDP With or Without Chidamide in Stage I/II Extranodal Nasal NK/T-cell Lymphoma

Not Applicable

Conditions: Lymphoma

Interventions: Drug: Chidamide

First Posted Date: 2020-08-13

Last Posted Date: 2020-08-13

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 76

Registration Number: NCT04511351

Locations: 🇨🇳
National Cancer Center, Cancer Hospital, Chinese Academy of Medical Scienses, Beijing, Beijing, China

Target Gene Sequencing for Advanced Stage, Relapsed or Refractory Natural Killer/T-cell Lymphoma

Completed

Conditions: Lymphoid Neoplasm

First Posted Date: 2020-08-12

Last Posted Date: 2020-08-12

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 26

Registration Number: NCT04509804

Locations: 🇨🇳
Mei Dong, Beijing, Beijing, China

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy